Comparison of Patient Characteristics and Outcome Between a Single-Institution Phase II Trial and a Cooperative-Group Phase II Trial with Identical Eligibility in Metastatic Melanoma-Reference-Cited by-同舟云学术

Comparison of Patient Characteristics and Outcome Between a Single-Institution Phase II Trial and a Cooperative-Group Phase II Trial with Identical Eligibility in Metastatic Melanoma

Published:1997-12 Issue:6 Volume:20 Page:600-604
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:American Journal of Clinical Oncology

Author:

Flaherty Lawrence E.,Liu P. Y.,Unger Joseph,Sondak Vernon K.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference33 articles.

1. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma

2. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

3. Dacarbazine and Outpatient Interleukin-2 in Treatment of Metastatic Malignant Melanoma: Phase II Southwest Oncology Group Trial

4. The Addition of Tamoxifen to Dacarbazine and Cisplatin in Metastatic Malignant Melanoma

5. Treatment of Metastatic Malignant Melanoma with Dacarbazine plus Tamoxifen

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials;JNCI: Journal of the National Cancer Institute;2019-06-20

2. Treatment Options for Limited or Symptomatic Metastatic Melanoma;Cancer Control;2008-07

3. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group;Journal of Cancer Research and Clinical Oncology;2007-03-03

4. Chemotherapy for metastatic melanoma;Cancer;2007

5. Reply concerning ?Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma? by Terheyden et al. (2004);Journal of Cancer Research and Clinical Oncology;2005-02-10